NDAINTRAVENOUSSOLUTION
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Clinical Trials (5)
A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets
Started Oct 2018
26 enrolled
Healthy
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
Started Sep 2013
28 enrolled
Arthritis, Rheumatoid
Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee
Started Oct 2011
408 enrolled
Osteoarthritis of the Knee
Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers
Started Nov 2008
6 enrolled
Healthy
A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis
Started Jul 2004
168 enrolled
Osteoarthritis
Loss of Exclusivity
LOE Date
Jul 31, 2041
187 months away
Patent Expiry
Jul 31, 2041
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 12263176 | Jul 31, 2041 | Product | — |
Company
R-Pharm US
NJ - Princeton